Figure 5: Increased PD-L1/CD86 ratio on pDCs of NRs before and after IFN/RBV treatment. PBMCs isolated from seronegative controls, NRs and SVRs were stained with polychromatic antibody cocktail described in supplementary Figure 1. (A) PD-L1/CD86 ratio on mDCs (calculated by dividing the percentage of mDCs expressing PD-L1 by the percentage of mDCs expressing CD86) of seronegative controls, NRs and SVRs before and after IFN/RBV treatment, (B) PD-L1/CD86 ratio on pDCs of seronegative controls, NRs and SVRs before and after IFN/RBV treatment. P values were calculated using Student’s t test (* represents P<0.05). Error bars represent standard deviation. (C) Dot plot representing the CD86 GMFI on pDCs of each NR along the course of therapy. (D) Dot plot representing the CD86 GMFI on pDCs of each SVR along the course of therapy.